focus -WSS

focus

author：entertainment 2025-08-26 07:42:22 - browse：5

Janet Woodcock -- health policy coverage from STAT — Janet Woodcock, the FDA's principal deputy commissioner Chip Somodevilla/Getty Images

WASHINGTON — It’s the end of an era for the Food and Drug Administration’s longtime drug chief, but she’s drawn the battle plans for the agency’s next chapter.

Janet Woodcock joined the FDA’s biologics division in 1986 but soon moved to the drug side, where over nearly three decades, she oversaw hundreds of reviews, new and evolving classes of therapies and several clashes with Congress and patient advocates. In recent years, she also warded off attacks on the agency’s decisionmaking during the Covid-19 pandemic, particularly when the agency veteran took the acting commissioner role during President Biden’s long search for a permanent leader, and took charge of a vast reorganization plan sparked by the baby formula crisis.

Some of those efforts still hang in the balance as she departs this week. Critics argue that under her oversight, the drug division worked too closely with pharmaceutical companies to give broad approvals to new medicines like Biogen’s Aduhelm or so-called accelerated approval to controversial therapies like Sarepta’s Duchenne muscular dystrophy medicine Exondys 51, which is still in the midst of post-marketing studies to prove its effectiveness.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： The high cost of giving birth even with insurance
Next article： Independent physicians launch a new lobbying group

WSS

Gilead’s Trodelvy fails in lung cancer, raises questions on ADCs

Listen: More tumult at BIO & coercive care for sickle cell patients

Biogen joins immunology wave with $1.15 billion acquisition of HI

eGenesis tests gene

Bird flu surveillance in wastewater gets boost from consortium

H5N1 bird flu outbreak: Second human case reported, in Michigan

hotspot

focus

focus

Medicare proposal to cover medical devices draws a mixed reaction

Liver decline slowed by off

Jerome Adams on the need for new antivirals for Covid

UnitedHealth argues against case alleging wrongful AI care denials

Guidelines to prevent youth baseball injuries need more muscle

AI generated plenty of interest at JPM but not a lot of trust

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Liver decline slowed by off

In age of alternative facts, a scholarly course on calling out crap

My yearlong odyssey to get my son’s ADHD medication covered

knowledge

Study finds gene variants tied to breast cancer risk in Black women

Eyeing GLP

My yearlong odyssey to get my son’s ADHD medication covered

The surgeon had a dilemma only a Nazi medical text could resolve

UnitedHealth argues against case alleging wrongful AI care denials

H5N1 bird flu outbreak: Second human case reported, in Michigan

entertainment

knowledge

entertainment

hotspot